Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing okay, thank you, given the circumstances. Our short person remains at home, toiling in front of a laptop. And our little official mascot is bounding about. So we are doing our best to forge ahead. No doubt, you may relate. So please join us for a needed cup of stimulation — we are back to glazed doughnut — and get set for another challenging day. On that note, we have assembled a few items of interest. Hope your day is manageable. Stay in touch, and stay safe. …

President Trump and his allies in conservative media have subtly scaled down their hyping of hydroxychloroquine as a potential treatment for the coronavirus, according to a Politico review of White House briefings and cable news coverage. Although Trump had repeatedly promoted the decades-old malaria drug since the early days of the pandemic outbreak in the U.S., his public statements regarding hydroxychloroquine have diminished significantly over the past week for reasons that remain unclear.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy